The Hindu Business Line : Ranbaxy ties up with Zenotech for oncology products

Ranbaxy Pharmaceuticals Inc (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Ltd (RLL), has entered into an agreement with the Hyderabad-based Zenotech Laboratories Ltd (ZLL) for oncology products development.

In a press release here on Wednesday, Zenotech said in terms of the agreement, it would develop, submit for regulatory approval and manufacture 11 oncology products that Ranbaxy would market as generic formulations in the USand Canada under the Ranbaxy label.

The combined branded sales of these products were estimated at $3.7 billion as per March 2006 statistics.

Zenotech is a speciality generic injectables company with a biotech core. Its predominantly high-value injectables product portfolios serve niche therapy areas such as oncology, anesthesiology, gynaecology, and neurology. It has full-fledged research and development facilities in India and in the US. Its oncology and biologics manufacturing facilities are located in India. RPI, based in Jacksonville, Florida, is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.

Zenotech CEO, Dr Jayaram Chigurupati, told Business Line that under the co-marketing agreement entered into, both the companies would be entitled to sell oncology products in the US and Canadian markets under their respective brands. "While we are using the existing facility for filing abbreviated new drug applications (ANDAs), we would manufacture the oncology products under the agreement from the new facility. The 100 per cent export oriented and fully dedicated unit, coming up in the Zenome Valley here on a 40-acre land, is expected to take off by December," Dr Chigurupati said.

Commenting on the agreement, the Ranbaxy CEO and Managing Director, Mr Malvinder M. Singh, said, "We are pleased with this arrangement. We anticipate a number of additional products materialising in the days ahead as a result of this mutually beneficial partnership."

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
IOC liquidates oil bonds worth Rs 835 cr

Air Deccan on revamp mode

`India cannot survive only as low-cost producer'

Ranbaxy ties up with Zenotech for oncology products

Genetix ties up with Labmate

SJS, Serigraph in joint venture

L&T approves 1:1 bonus issue

REL aims to generate 16,000 MW

Janapriya weighing fund-raising options

Biocon's cancer drug gets `favourable review'

Samtel to increase picture tube output

JCB India aims to boost sales in AP

Who will take over from Murthy in August?